ArticleFrontiers in oncology2026
Case Report: Prostate adenocarcinoma with peritoneal carcinomatosis and elevated CEA mimicking colorectal cancer: a diagnostic dilemma.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This case report describes an exceptionally rare manifestation of prostate adenocarcinoma presenting with peritoneal carcinomatosis, rectal obstruction, and markedly elevated carcinoembryonic antigen (CEA), closely mimicking colorectal cancer. A 65-year-old man with localized high-grade prostate adenocarcinoma (Gleason 4 + 4) underwent robotic prostatectomy in November 2020, followed by salvage radiation and stereotactic body radiation therapy for early biochemical recurrence. He achieved an excellent response to androgen deprivation therapy (ADT) combined with abiraterone and prednisone, maintaining an undetectable prostate-specific antigen (PSA) level for over 2 years. In late 2024, the patient developed hematochezia, narrow stools, and abdominal pain. Imaging revealed a rectal mass, diffuse peritoneal carcinomatosis, and new hepatic lesions. Despite an undetectable PSA, his serum CEA exceeded 7,000 ng/mL, strongly suggesting a colorectal primary. Multiple biopsies and immunohistochemical stains were inconclusive, showing poorly differentiated adenocarcinoma without definitive prostate or colorectal markers. Given the clinical presentation, FOLFOX chemotherapy was initiated empirically for presumed colorectal carcinoma. Next-generation sequencing (NGS) of rectal tissue ultimately identified a TMPRSS2::ERG fusion identical to that in the original prostatectomy specimen, strongly supporting a diagnosis of metastatic prostate adenocarcinoma origin. A subsequent liver biopsy corroborated the findings. The patient transitioned to docetaxel plus ADT, resulting in symptomatic improvement and partial radiologic response. Despite temporary stabilization, progressive bowel dysfunction required a palliative colostomy. Omental biopsies again confirmed metastatic prostate adenocarcinoma. This report underscores several key clinical lessons. First, peritoneal metastasis from prostate cancer is exceedingly uncommon and can masquerade as gastrointestinal malignancy, particularly when accompanied by high CEA levels and rectal involvement. Second, standard markers such as PSA and immunohistochemistry may be misleading in atypical presentations. Finally, the case highlights the decisive role of molecular diagnostics, specifically NGS, in identifying tumor origin and preventing misdiagnosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.